These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 23524525)

  • 1. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
    Maffioli P; Fogari E; D'Angelo A; Perrone T; Derosa G
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1113-22. PubMed ID: 23524525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load.
    Derosa G; Cicero AF; Fogari E; D'Angelo A; Bianchi L; Maffioli P
    Horm Metab Res; 2011 Jun; 43(7):505-12. PubMed ID: 21590648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
    Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Ciccarelli L; D'Angelo A; Fogari E; Maffioli P
    Can J Physiol Pharmacol; 2013 Sep; 91(9):724-32. PubMed ID: 23984793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
    Tan MH; Johns D; Strand J; Halse J; Madsbad S; Eriksson JW; Clausen J; Konkoy CS; Herz M;
    Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
    Kodama N; Tahara N; Tahara A; Honda A; Nitta Y; Mizoguchi M; Kaida H; Ishibashi M; Abe T; Ikeda H; Narula J; Fukumoto Y; Yamagishi S; Imaizumi T
    J Clin Endocrinol Metab; 2013 Nov; 98(11):4438-45. PubMed ID: 24030946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.
    Raz I; Stranks S; Filipczak R; Joshi P; Lertoft B; Rastam J; Chow CC; Shaban J
    Clin Ther; 2005 Sep; 27(9):1432-43. PubMed ID: 16291416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
    Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Piccinni MN; D'Angelo A; Fogari E; Maffioli P
    Diabetes Technol Ther; 2013 Mar; 15(3):214-22. PubMed ID: 23427864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
    Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
    Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy.
    Bellia A; Rizza S; Lombardo MF; Donadel G; Fabiano R; Andreadi K; Quon MJ; Sbraccia P; Federici M; Tesauro M; Cardillo C; Lauro D
    Atherosclerosis; 2012 Jul; 223(1):197-203. PubMed ID: 22658255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
    Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
    Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes.
    Comaschi M; Demicheli A; Di Pietro C; Bellatreccia A; Mariz S;
    Diabetes Technol Ther; 2007 Aug; 9(4):387-98. PubMed ID: 17705695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis.
    Fogari R; Maffioli P; Mugellini A; Zoppi A; Lazzari P; Derosa G
    Eur J Gastroenterol Hepatol; 2012 Feb; 24(2):164-71. PubMed ID: 22081005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
    Derosa G; Mereu R; Salvadeo SA; D'Angelo A; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
    Intern Med; 2009; 48(5):265-71. PubMed ID: 19252346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.